These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 23392600)

  • 21. Gut Microbiota-Medication Interaction in Rheumatic Diseases.
    Zhang L; Chu CQ
    Front Immunol; 2021; 12():796865. PubMed ID: 34925383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient-tailored therapy in rheumatoid arthritis: an editorial review.
    Scherer HU; Dörner T; Burmester GR
    Curr Opin Rheumatol; 2010 May; 22(3):237-45. PubMed ID: 20177384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. COVID-19 and rheumatology: Reflecting on the first wave and preparing for the second wave.
    Fardanesh A; Byravan S; Moorthy A; Tahir H
    Int J Rheum Dis; 2021 Jan; 24(1):7-9. PubMed ID: 33459529
    [No Abstract]   [Full Text] [Related]  

  • 24. Garden of therapeutic delights: new targets in rheumatic diseases.
    Waldburger JM; Firestein GS
    Arthritis Res Ther; 2009; 11(1):206. PubMed ID: 19232066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenomics in pediatric rheumatology.
    Becker ML
    Curr Opin Rheumatol; 2012 Sep; 24(5):541-7. PubMed ID: 22732686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of tuberculosis comparison in new users of antitumour necrosis factor-α and with existing disease-modifying antirheumatic drug therapy.
    Chan MJ; Wen YH; Huang YB; Chuang HY; Tain YL; Lily Wang YC; Hsu CN
    J Clin Pharm Ther; 2018 Apr; 43(2):256-264. PubMed ID: 29119581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biologic agents therapy for Saudi children with rheumatic diseases: indications and safety.
    Al-Mayouf SM; Alenazi A; AlJasser H
    Int J Rheum Dis; 2016 Jun; 19(6):600-5. PubMed ID: 24730661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The approach to precision medicine for the treatment of psoriatic arthritis.
    Miyagawa I; Tanaka Y
    Immunol Med; 2020 Sep; 43(3):98-102. PubMed ID: 32306849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Herbal medications commonly used in the practice of rheumatology: mechanisms of action, efficacy, and side effects.
    Setty AR; Sigal LH
    Semin Arthritis Rheum; 2005 Jun; 34(6):773-84. PubMed ID: 15942912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Non-TNF biologicals in therapy].
    Wollenhaupt J; Burmester GR
    Z Rheumatol; 2010 Sep; 69(7):579-80. PubMed ID: 20703491
    [No Abstract]   [Full Text] [Related]  

  • 31. [New biologics and orally available compounds. What is still in the pipeline?].
    Grünke M; Bastian H; Schulze-Koops H; Burmester GR
    Z Rheumatol; 2010 Sep; 69(7):626-32. PubMed ID: 20725732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacogenetics and pharmacogenomics in rheumatology.
    Szekanecz Z; Meskó B; Poliska S; Váncsa A; Szamosi S; Végh E; Simkovics E; Laki J; Kurkó J; Besenyei T; Mikecz K; Glant TT; Nagy L
    Immunol Res; 2013 Jul; 56(2-3):325-33. PubMed ID: 23564183
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent advances in Pediatric Rheumatology: July 2015-June 2016.
    Sharma A; Vignesh P; Jindal AK; Gupta A
    Int J Rheum Dis; 2017 Apr; 20(4):504-509. PubMed ID: 28205425
    [No Abstract]   [Full Text] [Related]  

  • 34. Mechanism of action of tumor necrosis factor antagonists. Proceedings of the Canadian expert roundtable meeting, Banff, Canada, November 28-30, 2003.
    J Rheumatol Suppl; 2005 Mar; 74():1-47. PubMed ID: 15742456
    [No Abstract]   [Full Text] [Related]  

  • 35. No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a two-year prospective study.
    Giardina AR; Ferraro D; Ciccia F; Ferrante A; Di Stefano R; Craxì A; Triolo G
    Clin Exp Rheumatol; 2013; 31(1):25-30. PubMed ID: 22935442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Personalized medicine: predicting responses to therapy in patients with RA.
    van den Broek M; Visser K; Allaart CF; Huizinga TW
    Curr Opin Pharmacol; 2013 Jun; 13(3):463-9. PubMed ID: 23578763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A short history of anti-rheumatic therapy--VII. Biological agents].
    Pasero G; Marson P; Gatto B
    Reumatismo; 2011 Nov; 63(3):185-94. PubMed ID: 22257920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proinflammatory cytokines synergistically enhance the production of chemokine ligand 20 (CCL20) from rheumatoid fibroblast-like synovial cells in vitro and serum CCL20 is reduced in vivo by biologic disease-modifying antirheumatic drugs.
    Kawashiri SY; Kawakami A; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Arima K; Kamachi M; Yamasaki S; Nakamura H; Tsurumoto T; Kono M; Shindo H; Ida H; Origuchi T; Eguchi K
    J Rheumatol; 2009 Nov; 36(11):2397-402. PubMed ID: 19797510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies.
    Cavalli G; Dinarello CA
    Rheumatology (Oxford); 2015 Dec; 54(12):2134-44. PubMed ID: 26209330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is it time to re-think juvenile-onset Rheumatic and Musculoskeletal Diseases? - First steps towards individualised treatments to meet agreed targets.
    McCann LJ; Hedrich CM
    Clin Immunol; 2021 Feb; 223():108647. PubMed ID: 33310069
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.